Noninflammatory Vascular Disease of the Kidney

  • Garabed Eknoyan

Abstract

The kidneys are highly vascularized organs that normally receive 20%–25% of the cardiac output. The arterial network of the kidney is highly specialized and is adapted to the regulatory functions of this organ. It is not unusual, therefore, to encounter functional and structural changes in the kidneys in diseases of the vasculature of any etiology. The compromise in renal function that ensues adversely affects, in turn, the course of the primary vascular disease. Conversely, the successful therapy of either the underlying vascular disease or the consequent deterioration of renal function will favorably alter the course of the other. This chapter deals only with the noninflammatory vascular diseases that compromise renal blood flow and alter renal function. The specific entities to be covered are high blood pressure, malignant hypertension, renovascular hypertension, scleroderma, embolic diseases, and renal vein thrombosis.

Keywords

Renal Artery Nephrotic Syndrome Renal Artery Stenosis Renovascular Hypertension Malignant Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Veterans Administration Cooperative Study on Anti-hypertensive Agents: Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 202: 1028 1034, 1967.Google Scholar
  2. 2.
    Veterans Administration Cooperative Study on Anti-hypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90–114 mmHg. JAMA 213: 1143–1152, 1970.CrossRefGoogle Scholar
  3. 3.
    Hypertension Detection and Follow-Up Cooperative Group: Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242: 2652–2671, 1979.Google Scholar
  4. 4.
    Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K: The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh blood pressure study. JAMA 264: 354–358, 1990.PubMedCrossRefGoogle Scholar
  5. 5.
    Kaplan NM: The role of the kidney in hypertension. Hypertension 1: 456–461, 1979.PubMedCrossRefGoogle Scholar
  6. Klahr S: The kidney in hypertension: villain and victim. N Engl J Med 320: 731–733, 1989.CrossRefGoogle Scholar
  7. 7.
    Zucchelli P, Zuccala A: Primary hypertension—how does it cause renal failure? Nephrol Dial Transplant 9: 223–225, 1994.PubMedGoogle Scholar
  8. 8.
    Whelton PK, Klag MJ: Hypertension as a risk factor for renal disease. Review of clinical and epidemiological evidence. Hypertension 13 (Suppl I): 19–27, 1989.CrossRefGoogle Scholar
  9. 9.
    Abraham PA, Mascioli SR, Launer CA, Flack JM, Liebson PR, Svensen KH, Grandits GA, Opsahl JA, Schoenberger JA, Grimm RH: Urinary albumin and N-acetyl-ß-D- glucosaminidase excretions in mild hypertension. Am J Hypertens 7: 965–974, 1994.PubMedCrossRefGoogle Scholar
  10. 10.
    Gilbert RE, Phillips P, Jerums G: Relationship between ambulatory blood pressure and albuminuria in normal subjects. Am J Hypertens 4: 959–962, 1991.PubMedCrossRefGoogle Scholar
  11. 11.
    Samuelson O: Proteinuria as a prognostic factor during long-term hypertensive care. Drugs 35 (Suppl 5): 48–54, 1988.CrossRefGoogle Scholar
  12. 12.
    Cerasola G, Cottone S, D’Ignoto G: Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1 (Suppl 6): S332 - S333, 1989.Google Scholar
  13. 13.
    Shulman NB, Ford CE, Hall D, Blaufox D, Simon D, Langford HE, Schneider KA: Prognostic value of serum creatinine on renal function. Results from the Hypertension Detection and Follow-up Program. Hypertension 13 (Suppl I): 80–93, 1989.CrossRefGoogle Scholar
  14. 14.
    Hall WD: Renal issues in the management of hypertension. Am J Hypertens 6: 245S - 250S, 1993.PubMedGoogle Scholar
  15. 15.
    Eknoyan G, Suki WN: Renal consequences of antihypertensive therapy. Semin Nephrol 11: 129–137, 1991.PubMedGoogle Scholar
  16. 16.
    Ferris TF: The kidney and hypertension. Arch Intern Med 142: 1889–1895, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Suki WN: The kidney in hypertension. Contrib Nephrol 7: 290–308, 1977.PubMedGoogle Scholar
  18. 18.
    Berglund G, Andersson O, Wilhelmsen L: Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 2: 554–558, 1976.PubMedCrossRefGoogle Scholar
  19. 19.
    US Renal Data System: USRDS 1993 Annual Data Report. The National Institute of Health, National Institute of Diabetes, Digestive and Kidney Disease, Bethesda, 1993.Google Scholar
  20. 20.
    Brunner FP, Seiwood NH: Profile of patients on renal replacement therapy in Europe and death rates due to major causes of death groups. Kidney Int 42 (Suppl 38): S4 - S15, 1992.Google Scholar
  21. 21.
    Lindeman RD, Tobin JD, Shock NW: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 26: 861–868, 1984.PubMedCrossRefGoogle Scholar
  22. 22.
    Moyer JH, Heider C, Pevey K, Ford RV: The vascular status of a heterogeneous group of patients with hypertension, with particular emphasis on renal function. Am J Med 24: 164–176, 1958.PubMedCrossRefGoogle Scholar
  23. 23.
    Rostand SG, Kirk KA, Rutsky EA, Pate BA: Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 306: 1276–1279, 1982.PubMedCrossRefGoogle Scholar
  24. 24.
    Zuccheli P, Zuccala A: Ischemic nephropathy in the elderly. Contrib Nephrol 105: 13–14, 1993.Google Scholar
  25. 25.
    Russell RP, Whelton PK: Hypertension in chronic renal failure. Clinical presentation, prognosis, pathophysiology and treatment. Am J Nephrol 3: 185–192, 1983.CrossRefGoogle Scholar
  26. 26.
    Sullivan JM, Johnson JG: The management of hypertension in patients with renal insufficiency. Semin Nephrol 3: 40–51, 1983.Google Scholar
  27. 27.
    Lifschitz MD: Hypertension in chronic renal failure. Contemp Issues Nephrol 4: 222–246, 1981.Google Scholar
  28. 28.
    Glatter KA, Graves SW, Hollenberg NK, Soszynski PA, Tao QF, Frem GJ, Williams GH, Lazarus JM: Sustained volumeexpansion and [Na,K] ATPase inhibition in chronic renal failure. Am J Hypertens 7: 1016–1025, 1994.PubMedGoogle Scholar
  29. 29.
    Vertes V, Cangano JL, Berman LB, Gould A: Hypertension in end-stage renal disease Engl J Med 280: 978–980, 1969.CrossRefGoogle Scholar
  30. 30.
    Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG: Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med 285: 757–762, 1971.PubMedCrossRefGoogle Scholar
  31. 31.
    Zuccheli P, Santoro A, Zuccala A: Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 8: 163–168, 1988.Google Scholar
  32. 32.
    Davies DL, Schalekampp MA, Beevers DG, Brown JJ, Briggs JD, Lever AF, Medina AM, Morton JJ, Robertson JIS, Tree M: Abnormal relation between exchangeable sodium and the renin-angiotensin system in malignant hypertension and in hypertension with chronic renal failure. Lancet 1: 683–687, 1973.PubMedCrossRefGoogle Scholar
  33. 33.
    Warren DJ, Ferris TF: Renin secretion in renal hypertension. Lancet 1: 149–163, 1970.Google Scholar
  34. 34.
    Weidmann P, Beretta-Piccoli C, Steffen F, Blumberg A, Reubi F: Hypertension in terminal renal failure. Kidney Int 9: 294–301, 1976.PubMedCrossRefGoogle Scholar
  35. 35.
    Campese VM, Romoff MS, Levitan D: Autonomic nervous system dysfunction in uremia. Kidney Int 19: 246–253, 1981.CrossRefGoogle Scholar
  36. 36.
    Morgenson CE: Progression of nephropathy in long-term diabetes with proteinuria and effect of initial antihypertension treatment. Scand J Clin Lab 36: 384–388, 1976.Google Scholar
  37. 37.
    Woods JW, Blythe WB: Management of malignant hypertension complicated by renal insufficiency. N Engl J Med 277: 57–61, 1967.PubMedCrossRefGoogle Scholar
  38. 38.
    Woods JW, Blythe WB, Huffines WD: Management of malignant hypertension complicated by renal insufficiency. N Engl J Med 291: 10–14, 1974.PubMedCrossRefGoogle Scholar
  39. 39.
    Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 35: 670–674, 1989.PubMedCrossRefGoogle Scholar
  40. 40.
    Okuda S, Onoyama K, Fujimi S, Oh Y, Nomoto K, Omae T: Influence of hypertension on the progression of experimental autologous immune complex nephritis. J Lab Clin Med 101: 461–470, 1983.PubMedGoogle Scholar
  41. 41.
    Brenner BM: Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23: 647–655, 1983.PubMedCrossRefGoogle Scholar
  42. 42.
    Yoshida Y, Fogo A, Ichikawa I: Glomerular hemodynamic changes vs hypertrophy in experimental glomerular sclerosis. Kidney Int 35: 654–660, 1989.PubMedCrossRefGoogle Scholar
  43. 43.
    Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384–394, 1990.PubMedCrossRefGoogle Scholar
  44. 44.
    Diamond JR, Karnovsky MI: Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33: 917–924, 1988.PubMedCrossRefGoogle Scholar
  45. 45.
    National High Blood Pressure Eduction Program: National High Blood Pressure Education Program Working Group Report on Hypertension and Chronic Renal Failure. Arch Intern Med 151: 1280–1287, 1991.CrossRefGoogle Scholar
  46. 46.
    The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). October 1992.Google Scholar
  47. 47.
    Jacobson H, Striker GE: Report of a workshop to develop management recommendations for the prevention of progression of chronic renal disease. J Am Soc Nephrol, in press.Google Scholar
  48. 48.
    Rettig R: The kidney as a determinant of hypertension. Nephrol Dial Transplant 8: 1317–1318, 1993.PubMedGoogle Scholar
  49. 49.
    Rettig R, Folberth C, Strauss H, Kopf D, Waldherr R, Unger T: Role of the kidney in primary hypertension: A renal transplantation study in rats. Am J Physiol 258: F606 - F611, 1990.PubMedGoogle Scholar
  50. 50.
    Graf C, Maser-Gluth C, De Muinck Keizer W, Rettig R: Sodium retention and hypertension after kidney transplantation in rats. Hypertension 21: 724–730, 1993.PubMedCrossRefGoogle Scholar
  51. 51.
    Guidi E, Bianchi G, Rivolta E, Ponticelli C, Palo FQ, Minetti L, Polli E: Hypertension in man with a kidney transplant: Role of familial versus other factors. Nephron 41: 14–21, 1985.PubMedCrossRefGoogle Scholar
  52. 52.
    Freis ED: Does moderate sodium restriction lower blood pressure? Hypertension 8: 265–266, 1986.PubMedCrossRefGoogle Scholar
  53. 53.
    Ram CVS, Garrett BN, Kaplan NM: Moderate sodium restriction and various diuretics in the treatment of hypertension. Effects of potassium wastage and blood pressure control. Arch Intern Med 141: 1015–1019, 1981.PubMedCrossRefGoogle Scholar
  54. 54.
    Kaplan NM: Management strategies in hypertension. Contemp Issues Nephrol 4: 339–366, 1981.Google Scholar
  55. 55.
    Suki WN, Dawoud F, Eknoyan G, Martinez-Maldonado M: Effects of metolazone on renal function in normal man. J Pharmacol Exp Ther 180: 6–12, 1972.PubMedGoogle Scholar
  56. 56.
    Frishman WH: ß-adrenoreceptor antagonists: new drugs and new indications. N Engl J Med 305: 500–506, 1981.PubMedCrossRefGoogle Scholar
  57. 57.
    The Norwegian Multi-Center Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304: 801–807, 1981.CrossRefGoogle Scholar
  58. 58.
    Braunwald E, Muller JE, Kloner RA, Maroko PR: Role of beta-adrenergic blockade in the therapy of patients with myocardial infarction. Am J Med 74: 113–123, 1983.PubMedCrossRefGoogle Scholar
  59. 59.
    Weber MA, Drayer JIM: Renal effects of beta-adrenoreceptor-blockade. Kidney Int 18: 686–699, 1980.PubMedCrossRefGoogle Scholar
  60. 60.
    Wright AD, Barber SG, Kendall MJ: Beta-adrenoreceptor blocking drugs and blood sugar control in diabetes mellitus. Br Med J 1: 159–161, 1979.PubMedCrossRefGoogle Scholar
  61. 61.
    Greenblatt DJ, Koch-Wesser J: Adverse reactions to propranolol in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J 86: 478–485, 1973.PubMedCrossRefGoogle Scholar
  62. 62.
    Rosa RM, Silva P, Young JB, Brown RS, Rowe JW, Epstein FH: Adrenergic modulation of extrarenal potassium disposal. N Engl J Med 302: 431–434, 1980.PubMedCrossRefGoogle Scholar
  63. 63.
    Fröhlich ED: Methyldopa. Mechanism and treatment 25 years later. Arch Intern Med 140: 954–959, 1981.CrossRefGoogle Scholar
  64. 64.
    Pettinger WA: Clonidine, a new antihypertensive drug. N Engl J Med 293: 1179–1180, 1975.PubMedCrossRefGoogle Scholar
  65. 65.
    Saameli K, Jerie P, Scholtysik G: Guanfacine and other centrally acting drugs in antihypertensive therapy: pharmacological and clinical aspects. Clin Exp Hypertens [A] 4: 209–219, 1982.CrossRefGoogle Scholar
  66. 66.
    Chidsey CA, Gottlieb TB: The pharmacological basis of antihypertensive therapy: the role of vasodilator drugs. Prog Cardiovasc Dis 17: 99–113, 1974.PubMedCrossRefGoogle Scholar
  67. 67.
    Koch-Wesser J: Hydralazine. N Engl J Med 295: 61–65, 1981.Google Scholar
  68. 68.
    Graham RM, Pettinger WA: Prazosin. N Engl J Med 300: 232–236, 1979.PubMedCrossRefGoogle Scholar
  69. 69.
    Veterans Administration Cooperative Study on Antihypertensive Agents: Comparison of prazosin with hydralazine in patients receiving hydrochlorothiazide. A randomized, double-blind clinical trial. Circulation 64: 772–779, 1981.CrossRefGoogle Scholar
  70. 70.
    Keusch GW, Weidmann P, Campese V, Lee DBN, Upham AT, Massry SG: Minoxidil therapy in refractory hypertension. Analysis of 155 patients. Nephron 21: 1–15, 1979.CrossRefGoogle Scholar
  71. 71.
    Mitchell JC, Graham RM, Pettinger WA: Renal function during long-term treatment of hypertension with minoxidil. Comparison of benign and malignant hypertension. Ann Intern Med 93: 676–681, 1980.PubMedCrossRefGoogle Scholar
  72. 72.
    Ram CVS: Clinical application of therapeutic advances. Captopril. Arch Intern Med 142: 914–916, 1982.PubMedCrossRefGoogle Scholar
  73. 73.
    Rubin B, Antonaccio MJ, Horowitz ZP: Captopril: a new orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent. Prog Cardiovasc Dis 21: 183–187, 1978.PubMedCrossRefGoogle Scholar
  74. 74.
    Vidt DG, Bravo EL, Fouad FM: Captopril. N Engl J Med 306: 214–219, 1982.PubMedCrossRefGoogle Scholar
  75. 75.
    Bauer JH, Reams GP, Lai SM: Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 147: 1397–1400, 1987.PubMedCrossRefGoogle Scholar
  76. 76.
    Zatz R, Anderson S, Meyer TW, Dunn BR, Rennke HG, Brenner BM: Lowering arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney Int 31 (Suppl 20): S123 - S129, 1987.Google Scholar
  77. 77.
    Hostetter TH, Rennke HG, Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 73: 375–380, 1982.CrossRefGoogle Scholar
  78. 78.
    Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293: 471–474, 1986.CrossRefGoogle Scholar
  79. 79.
    Hommel E, Parving HH, Mathiesen E, Edsberg B, Damkjaer NM, Geise J: Effect of Captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 293: 467–170, 1986.CrossRefGoogle Scholar
  80. 80.
    Parving HH, Hommel E, Schmidt UM: Protection of kidney function and decrease in albuminuria by Captopril in insulin-dependent diabetics with nephropathy. Br Med J 297: 1086–1091, 1988.CrossRefGoogle Scholar
  81. 81.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotension-converting-enzyme inhibition of diabetic nephropathy. N Engl] Med 329: 1456–1462, 1993.CrossRefGoogle Scholar
  82. 82.
    Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus. Am J Kidney Dis 25: 107–112, 1995.PubMedCrossRefGoogle Scholar
  83. 83.
    Bauer JH, Reams GP, Lai SM: Renal protective effect of strict blood pressure control with enalapril therapy. Arch Intern Med 147: 1397–1400, 1987.PubMedCrossRefGoogle Scholar
  84. 84.
    Keane WF, Anderson S, Aurell M, Zeeuw D, Narins NG, Povan G: Angiotension-converting enzyme inhibitors and progressive renal insufficiency. Ann Intern Med 111: 503–516, 1989.PubMedCrossRefGoogle Scholar
  85. 85.
    Mann JFE, Reisch C, Ritz E: Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. A retrospective study. Nephron 55 (Suppl l): 38–42, 1990.PubMedCrossRefGoogle Scholar
  86. 86.
    Levenson DJ, Dzau VJ: Effects of angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis. Kidney Int 31 (Suppl 20): S173 - S179, 1987.Google Scholar
  87. 87.
    Mujais SK, Fouad FM, Texor SC, Tarazi RC, Bravo EL, Hart N, Gifford RW: Transient renal dysfunction during initial inhibition of converting enzyme in congestive heart failure. Br Heart J 52: 63–71, 1984.PubMedCrossRefGoogle Scholar
  88. 88.
    Textor SC, Bravo E, Fouad FM: Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with Captopril. Am J Med 73: 719–725, 1982.PubMedCrossRefGoogle Scholar
  89. 89.
    Ram CVS: Calcium antagonists in the treatment of hypertension. Am J Med Sei 290: 118–133, 1985.CrossRefGoogle Scholar
  90. 90.
    Loutzenhizer R, Epstein M: Effects of calcium antagonists on renal hemodynamics. An editorial review. Am J Physiol 249: F616 - F621, 1985.Google Scholar
  91. 91.
    Chan L, Schrier RW: Effects of calcium-channel blockers on renal function. Annu Rev Med 41: 289–309, 1990.PubMedCrossRefGoogle Scholar
  92. 92.
    Sunderrajan S, Reams G, Bauer JH: Long-term renal effects of diltiazem in essential hypertension. Am Heart J 114: 383–388, 1987.PubMedCrossRefGoogle Scholar
  93. 93.
    Reams GP, Hamory A, Lau A, Bauer JH: Effect of nifedipine on renal function in patients with essential hypertension. Hypertension 11: 452–456, 1988.PubMedCrossRefGoogle Scholar
  94. 94.
    Huthen UL, Katzman PL: Renal effects of acute and long-term treatment with felodipine in hypertension. J Hypertens 6: 231–237, 1988.CrossRefGoogle Scholar
  95. 95.
    Mimran A, Insua A, Ribstein J, Momaier L, Bringer J, Mirouze J: Contrasting effects of Captopril and nifedipine in normotensive patients with diabetic nephropathy. J Hypertens 6: 919–923, 1988.PubMedCrossRefGoogle Scholar
  96. 96.
    Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112: 707–708, 1990.PubMedCrossRefGoogle Scholar
  97. 97.
    Brazy PC, Fitzwilliam JF: Progressive renal disease: role of race and antihypertensive medications. Kidney Int 37: 1113–1119, 1990.PubMedCrossRefGoogle Scholar
  98. 98.
    Epstein M: Calcium antagonists and the kidney: implications for renal protection. Am J Hypertens 6: 251S - 259S, 1993.PubMedGoogle Scholar
  99. 99.
    Koch-Weser J: Hypertensive emergencies. N Engl J Med 290: 1367–1369, 1975.Google Scholar
  100. 100.
    Keith TA: Hypertension crisis. Recognition and management. JAMA 237: 1570–1577, 1977.PubMedCrossRefGoogle Scholar
  101. 101.
    Carry CL: Current treatment of malignant hypertension. JAMA 232: 1367–1369, 1975.CrossRefGoogle Scholar
  102. 102.
    Ram CVS: Hypertensive encephalopathy—recognition and management. Arch Intern Med 138: 1851–1853, 1978.PubMedCrossRefGoogle Scholar
  103. 103.
    Bhatia SK, Fröhlich ED: Hemodynamic comparison of agents useful in hypertensive emergencies. Am Heart J 85: 367–373, 1973.CrossRefGoogle Scholar
  104. 104.
    Calhoun DA, Oparil S: Treatment of hypertensive crises. N Engl J Med 323: 1177–1183, 1990.PubMedCrossRefGoogle Scholar
  105. 105.
    Gifford RW: Management of hypertensive crises. JAMA 266: 829–835, 1991.PubMedCrossRefGoogle Scholar
  106. 106.
    Cohn JH, Burke LP: Nitroprusside. Ann Intern Med 91: 752–757, 1979.PubMedCrossRefGoogle Scholar
  107. 107.
    Ram CVS, Kaplan NM: Individual titration of diazoxide dosage in the treatment of severe hypertension. Am J Cardiol 43: 627–630, 1979.PubMedCrossRefGoogle Scholar
  108. 108.
    Houston MC: Treatment of hypertensive emergencies and urgencies with oral Clonidine loading and titration. A review. Arch Intern Med 146: 586–589, 1986.PubMedCrossRefGoogle Scholar
  109. 109.
    Haft JI, Litterer WE: Chewing nifedipine to rapidly treat hypertension. Arch Intern Med 144: 2357–2359, 1984.PubMedCrossRefGoogle Scholar
  110. 110.
    Wilson DJ, Wallin JD, Vlachakis ND, Freis ED, Vidt DG, Michelson EL, Langford HG, Flamenbaum W, Poland MP: Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med 74: 95–102, 1983.CrossRefGoogle Scholar
  111. 111.
    Brollaz J, Waeber B, Brunner HR: Hypertensive crisis treated with orally administered Captopril. Eur J Clin Pharmacol 25: 145–149, 1983.CrossRefGoogle Scholar
  112. 112.
    Reams GP, Lai SM, Whalen JJ, Bauer JH: Enalaprilat—an intravenous substitute for oral enalapril therapy. J Clin Hypertens 3: 245–253, 1986.Google Scholar
  113. 113.
    DiPette DJ, Ferraro JC, Evans RR: Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor in hypertensive crisis. Clin Pharmacol Ther 38: 199–204, 1985.PubMedCrossRefGoogle Scholar
  114. 114.
    Byron FB: The evolution of acute hypertensive arterial disease. Prog Cardiovasc Dis 17: 31–37, 1974.CrossRefGoogle Scholar
  115. 115.
    MacMahon HE: Malignant nephrosclerosis—a reappraisal. Pathol Ann 3: 297–334, 1968.Google Scholar
  116. 116.
    Allison PR, Bleeham N, Brown W, Pickering GW, Robb- Smith AHT, Russell RP: The production and resolution of hypertensive vascular lesions in the rabbit. Clin Sei 33: 39–51, 1967.Google Scholar
  117. 117.
    Pickering G: Reversibility of malignant hypertension. Follow-up of three cases. Lancet 1: 413–418, 1971.PubMedCrossRefGoogle Scholar
  118. 118.
    Mroczek WJ, Davidov M, Gavrilovich L, Finnerty F: The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 40: 893–904, 1969.PubMedCrossRefGoogle Scholar
  119. 119.
    Lawton WJ: The short-term course of renal function in malignant hypertensives with renal insuffiency. Clin Nephrol 17: 277–283, 1982.PubMedGoogle Scholar
  120. 120.
    Friedlander MM, Rubinger D, Popovtzer MM: Improved renal function in patients with primary renal disease after control of severe hypertension. Am J Nephrol 2: 12–14, 1982.CrossRefGoogle Scholar
  121. 121.
    Eknoyan G, Siegel MB: Survival from anuria due to malignant hypertension. JAMA 215: 1122–1125, 1971.PubMedCrossRefGoogle Scholar
  122. 122.
    Dichoso CC, Minuth ANW, Eknoyan G: Malignant hypertension: recovery of kidney function after renal allograft failure. Arch Intern Med 135: 300–303, 1975.PubMedCrossRefGoogle Scholar
  123. 123.
    Ram CVS, Hyman D: Hypertensive crisis. J Intensive Care Med 2: 151–162, 1987.CrossRefGoogle Scholar
  124. 124.
    Mahoney JF, Gibson GR, Shiel AGR, Storey BG, Stokes GS, Stewart JH: Bilateral nephrectomy for malignant hypertension. Lancet 1: 1036–1038, 1972.CrossRefGoogle Scholar
  125. 125.
    McCarron DA, Rubin RJ, Varnes BA, Harrington JT, Nillan EG: Therapeutic bilateral renal infarction in end-stage renal disease. N Engl J Med 294: 652, 1976.PubMedCrossRefGoogle Scholar
  126. 126.
    Pettinger WA, Mitchell JC: Minoxidil. An alternative to nephrectomy for refractory hypertension. N Engl J Med 289: 167–171, 1973.PubMedCrossRefGoogle Scholar
  127. 127.
    Mroczek WJ: Malignant hypertension: kidneys too good to be extirpated. Ann Intern Med 80: 754–757, 1974.PubMedCrossRefGoogle Scholar
  128. 128.
    Rimmer JM, Gennari FJ: Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med 118:712— 719,1993.Google Scholar
  129. 129.
    Maxwell MH, Bleifer KH, Franklin SJ, Varady PO: Demographic analysis of study. JAMA 220: 1195–1209, 1972.PubMedCrossRefGoogle Scholar
  130. 130.
    Simon N, Franklin SS, Bleifer KH, Maxwell MH: Characteristics of renovascular hypertension. JAMA 220: 1209–1218, 1972.PubMedCrossRefGoogle Scholar
  131. 131.
    Hunt JC, Scheps SG, Harrison EG, Strong CG, Bernatz PE: Renal and renovascular hypertension. A reasoned approach to diagnosis and management. Arch Intern Med 133: 988–999, 1974.PubMedCrossRefGoogle Scholar
  132. 132.
    Working Group on Renovascular Hypertension: Detection, evaluation, and treatment of renovascular hypertension. Final report. Arch Intern Med 147: 820–829, 1987.CrossRefGoogle Scholar
  133. 133.
    Jacobson HR: Ischemic renal disease: an overlooked clinical entity? Kidney Int 34: 729–743, 1988.PubMedCrossRefGoogle Scholar
  134. 134.
    Grim CE, Weinberger MH: Renal artery stenosis and hypertension. Semin Nephrol 3: 52–64, 1983.Google Scholar
  135. 135.
    Missouris CG, Buckenham T, Cappucio FP, Mac Gregor GH: Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. Am J Med 96: 10–14, 1994.PubMedCrossRefGoogle Scholar
  136. 136.
    Schreiber MJ, Pohl MA, Novick AC: Preserving renal function by revascularization. Annu Rev Med 41: 423–429, 1990.PubMedCrossRefGoogle Scholar
  137. 137.
    Mailloux LU, Bellucci AG, Mossey RT, Napolitano B, Moore T, Wilkes BM: Predictors of survival in patients undergoing dialysis. Am J Med 84: 855–862, 1988.PubMedCrossRefGoogle Scholar
  138. 138.
    Dzau VJ, Gibbons GH, Levin DC: Renovascular hypertension: an update on pathophysiology, diagnosis and treatment. Am J Nephrol 3: 172–184, 1983.PubMedCrossRefGoogle Scholar
  139. 139.
    Brookstein JJ, Abrams HL, Buenger RE, Lecky J, Franklin SS, Reis MD, Bleifer KH, Klatte EC, Varady PD, Maxwell MH: Urography in unilateral renovascular disease. JAMA 220: 1225–1230, 1972.CrossRefGoogle Scholar
  140. 140.
    Grim CE, Luft FC, Weinberger MH, Grim CM: Sensitivity and specificity of screening tests for renal vascular hypertension. Ann Intern Med 91: 617–622, 1979.PubMedCrossRefGoogle Scholar
  141. 141.
    McNeil BJ, Varady PD, Burrows BA, Adelstein SJ: Measures of clinical efficacy: cost effectiveness calculation in the diagnosis and treatment of hypertensive renovascular disease. N Engl J Med 293: 216–221, 1975.PubMedCrossRefGoogle Scholar
  142. 142.
    Hollenberg NK, Williams GH, Adams DF, Moore T, Brown C, Boruki LJ, Leung F, Bavli S, Solomon HS, Passan D, Dluhy R: Response to saralasin and angiotensin role in essential and renal hypertension. Medicine 58: 115–127, 1979.PubMedCrossRefGoogle Scholar
  143. 143.
    Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN: Clinical experience with blockade of the renin-angiotensin aldosterone system by an oral converting-enzyme inhibitor (SQ14225, Captopril) in hypertensive patients. Prog Cardiovasc Dis 21: 195–206, 1978.PubMedCrossRefGoogle Scholar
  144. 144.
    Staessen J, Wilms G, Baert A, Fagard R, Lynen P, Suy R, Amery A: Blood pressure during long-term convertining-enzyme inhibition predicts the curability of renovascular hypertension by angioplasty. Am J Hypertens 1: 208–214, 1988.PubMedCrossRefGoogle Scholar
  145. 145.
    Navis G, de Jong PE, Donker AJM, van der Hem GK, de Zeeuw D: Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition. Kidney Int 31: 815–819, 1987.PubMedCrossRefGoogle Scholar
  146. 146.
    Sealey JE, Buhler FR, Laragh JH, Vaughan D: The physiology of renin secretion in essential hypertension: estimation of renin secretion rate and renal plasma flow from peripheral and renal vein renin levels. Am J Med 55: 391–401. 1973.PubMedCrossRefGoogle Scholar
  147. 147.
    Marks LS, Maxwell MH: Renal vein renin. Value and limitations in the prediction of operative results. Urol Clin North Am 2: 311–325, 1975.PubMedGoogle Scholar
  148. 148.
    Vaughan ED, Buehler FR, Laragh JH, Sealey JE, Baer L, Bard RH: Renovascular hypertension: renin measurement to indicate hypersecretion and contralateral suppression, estimate renal blood flow, and score for surgical curability. Am J Med 65:402-114,1973.Google Scholar
  149. 149.
    Sos TA, Pickering TG, Sniderman K, Saddekin S, Case DB, Silane MF, Vaughan ED, Laragh JH: Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. N Engl J Med 309: 274–279, 1983.PubMedCrossRefGoogle Scholar
  150. 150.
    Madias NE: Renovascular hypertension. Nephrol Lett 3: 27–42, 1986.Google Scholar
  151. 151.
    Mann SJ, Pickering TG: Detection of renovascular hypertension. State of the art. Ann Intern Med 117: 845–853, 1992.PubMedCrossRefGoogle Scholar
  152. 152.
    Davidson RA, Wilcox CS: Newer tests for the detection of renovascular disease. JAMA 268: 3353, 3358, 1992.Google Scholar
  153. 153.
    Martin LG, Price RB, Casarekka WJ, Stones PJ, Wells, SO, Zellmer RA, Chuang VP, Silbiger ML, Berkman WA: Percutaneous angioplasty in clinical management of renovascular hypertension: initial and long-term results. Radiology 155: 629–633, 1985.PubMedGoogle Scholar
  154. 154.
    Krener HTK, de Jong PE, de Zeeuw D, Donker AMJ, Schuur KH, van der Hem GK: Restenosis prevalence and long-term effects on renal function after percutaneous transluminal renal angioplasty. Nephrol 44 (Suppl l): 64–67, 1986.Google Scholar
  155. 155.
    Geyskes GG: Treatment of renovascular hypertension with percutaneous transluminal renal angioplasty. Am J Kidney Dis 12: 253–265, 1988.PubMedGoogle Scholar
  156. 156.
    Hansen KJ, Starr SM, Sands E, Burhart JM, Plonk GW, Dean R: Contemporary surgical management of renovascular disease. J Vase Surg 16: 319–331, 1992.CrossRefGoogle Scholar
  157. 157.
    Buhler FR, Laragh JH, Vaughan ED, Brunner HR, Gavras H, Baer L: The antihypertensive action of propranolol. Specific anti-renin response in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 32: 511–522, 1973.PubMedCrossRefGoogle Scholar
  158. 158.
    Case DB, Atlas SA, Marion RM, Laragh JH: Long-term efficacy of Captopril in renovascular and essential hypertension. Am J Cardiol 49: 1440–1446, 1982.PubMedCrossRefGoogle Scholar
  159. 159.
    Aldigier JC, Ploum P, Guyene IT, Thibonnier M, Carval P, Menard J: Comparison of the hormonal and renal effects of Captopril in severe essential and renovascular hypertension. Am J Cardiol 49: 1447–1452, 1982.PubMedCrossRefGoogle Scholar
  160. 160.
    Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ: Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal artery stenosis in a solitary kidney. N Engl J Med 308: 373–376, 1983.PubMedCrossRefGoogle Scholar
  161. 161.
    Hricik DE, Dunn MJ: Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1: 845–858, 1990.PubMedGoogle Scholar
  162. 162.
    Jackson B, Franze L, Sumithran E, Johnson CI: Pharmacologic nephrectomy with chronic angiotensin-converting enzyme inhibitor treatment in renovascular hypertension in the rat. J Lab Clin Med 115: 21–27, 1990.PubMedGoogle Scholar
  163. 163.
    Orabona ML, Albano O: Systemic progressive sclerosis. Acta Med Scand 333 (Suppl):l-170, 1958.Google Scholar
  164. 164.
    Winkelmann RK: Classification and pathogenesis of scleroderma. Mayo Clin Proc 46: 83–91, 1971.PubMedGoogle Scholar
  165. 165.
    Eknoyan G, Suki WN: Renal vascular phenomena in systemic sclerosis. Semin Nephrol 5: 34–45, 1985.PubMedGoogle Scholar
  166. 166.
    Norton WL, Nardo JM: Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 73: 317–324, 1970.PubMedCrossRefGoogle Scholar
  167. 167.
    Geppert T: Clinical features, pathogenic mechanisms, and new developments in the treatment of systemic sclerosis. Am J Med Sei 299: 193–209, 1990.CrossRefGoogle Scholar
  168. 168.
    Medsger TA, Masi AT, Rodnan GP, Benedek TG, Robinson H: Survival with systemic sclerosis (scleroderma): a life-table analysis of demographic and clinical factors in 309 patients. Ann Intern Med 75: 369–376, 1971.PubMedCrossRefGoogle Scholar
  169. 169.
    Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy C: The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 53: 1–46, 1974.PubMedCrossRefGoogle Scholar
  170. 170.
    Hannigan CA, Hannigan MH, Scoh EL: Scleroderma of the kidneys. Am J Med 20: 793–797, 1956.PubMedCrossRefGoogle Scholar
  171. 171.
    Rodnan GP, Schreiner GE, Black RL: Renal involvement in progressive systemic sclerosis (generalized scleroderma). Am J Med 23: 445–462, 1957.PubMedCrossRefGoogle Scholar
  172. 172.
    Fisher ER, Rodnan GP: Pathologic observations concerning the kidney in progressive systemic sclerosis. Arch Pathol 65: 29–39, 1958.Google Scholar
  173. 173.
    Lapenas D, Rodnan GP, Cavallo T: Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma). Am J Pathol 91: 243–258, 1978.PubMedGoogle Scholar
  174. 174.
    Medsger TA, Masi AT: Survival with scleroderma-II: a life-table analysis of clinical and demographic factors in 358 males U.S. veteran patients. J Chron Dis 26: 647–660, 1973.PubMedCrossRefGoogle Scholar
  175. 175.
    Richardson JA: Hemodialysis and kidney transplantation for renal failure from scleroderma. Arthritis Rheum 16: 265–271, 1973.PubMedCrossRefGoogle Scholar
  176. 176.
    Shapiro CB, Lerner NE, Achad AS, Abramson R, Stein RM: Malignant hypertension and uremia in scleroderma: efficacy of nephrectomy and hemodialysis. Clin Nephrol 8:321–323Google Scholar
  177. 177.
    Dichoso CC: The kidney in progressive systemic sclerosis (scleroderma). In: WN Suki, G Eknoyan, eds, The Kidney in Systemic Disease, 2nd ed. John Wiley & Sons, New York, pp 109–128, 1981.Google Scholar
  178. 178.
    Brown ST, Ahearn DJ, Nolph KD: Reduced peritoneal clearance in scleroderma increased by intraperitoneal isoproterenol. Ann Intern Med 78: 891–894, 1973.PubMedCrossRefGoogle Scholar
  179. 179.
    Oliver JA, Cannon PJ: The kidney in scleroderma. Nephron 18: 141–150, 1977.PubMedCrossRefGoogle Scholar
  180. 180.
    LeRoy EC, Fleischmann RM: The management of renal scleroderma: experience with dialysis, nephrectomy, and transplantation. Am J Med 64: 974–978, 1978.PubMedCrossRefGoogle Scholar
  181. 181.
    Keane WF, Danielson B, Raij L: Successful renal transplantation in progressive systemic sclerosis. Ann Intern Med 85: 199–202, 1976.PubMedCrossRefGoogle Scholar
  182. 182.
    Stone RA, Tisher CC, Hawkins HK, Robinson RR: Juxtaglomerular hyperplasia and hyperreninemia in progressive systemic sclerosis complicated by acute renal failure. Am J Med 56: 119–123, 1974.PubMedCrossRefGoogle Scholar
  183. 183.
    Kovalchik MT, Guggenheim SJ, Silverman MH, Robertson JS, Steigerwald JC: The kidney in progressive systemic sclerosis: a prospective study. Ann Intern Med 89: 881–887, 1978.PubMedCrossRefGoogle Scholar
  184. 184.
    Gavras H, Gavras I, Cannon PH, Brunner HR, Laragh JH: Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis? Arch Intern Med 137: 1554–1558, 1977.PubMedCrossRefGoogle Scholar
  185. 185.
    Moorthy AV, Wu MJ, Bierne GJ, Sundstron WS: Control of hypertension and acute renal failure in scleroderma without nephrectomy. Lancet 1: 563–564, 1978.PubMedGoogle Scholar
  186. 186.
    Mitnich PD, Fieg PU: Control of hypertension and reversal of renal failure in scleroderma. N Engl J Med 299:871–872Google Scholar
  187. 187.
    Wasner C, Cooke CR, Fries JF: Successful medical treatment of scleroderma renal crisis. N Engl J Med 299: 873–875, 1978.PubMedCrossRefGoogle Scholar
  188. 188.
    Lopez-Overjero JA, Saal SD, D’Angelo WA, Cheigh JS, Stenzel KH, Laragh JH: Reversal of vascular and renal crisis of scleroderma by oral angiotensin-converting enzyme blockade. N Engl J Med 300: 1417–1419, 1979.CrossRefGoogle Scholar
  189. 189.
    Beckett VL, Donadio JV, Breman LA, Conn DL, Omundson PJ, Chao EYS, Holley KE: Use of Captopril as early therapy for renal scleroderma: a prospective study. Mayo Clin Proc 60: 763–771, 1985.PubMedCrossRefGoogle Scholar
  190. 190.
    Whitman HH, Case, DB, Laragh JH, Christian CL, Botstein G, Maricq H, LeRoy EC: Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Arthritis Rheum 25: 241–248, 1982.PubMedCrossRefGoogle Scholar
  191. 191.
    Steen VD, Costantino JP, Shapiro A, Medsger TA: Outcome of renal crisis in systemic sclerosis: relation to availability of converting enzyme (ACE) inhibitors. Ann Intern Med 113: 352–357, 1990.PubMedCrossRefGoogle Scholar
  192. 192.
    Finch MB, Dawson J, Johnson GD: The peripheral vascular effects of nifedipine in Raynaud’s syndrome associated with scleroderma: a double-blind crossover study. Clin Rheumatol 5: 493–498, 1986.PubMedGoogle Scholar
  193. 193.
    Waldo R: Prazosin relieves Raynaud’s vasospasm. JAMA 241: 1037, 1979.PubMedCrossRefGoogle Scholar
  194. 194.
    Winkelmann RK, Kierland RR, Perry HO, Muller SA, Sams WM: Management of scleroderma. Mayo Clin Proc 46: 128–134, 1971.PubMedGoogle Scholar
  195. 195.
    Rodnan GP: Progressive systemic sclerosis (scleroderma). In Samler, ed, Immunological Diseases, vol. II. Little, Brown, Boston, pp 1109–1141, 1978.Google Scholar
  196. 196.
    LeRoy EC: A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 51: 286–288, 1992.PubMedCrossRefGoogle Scholar
  197. 197.
    Torres MA, Fürst DE: Treatment of generalized systemic sclerosis. Rheum Dis Clin North Am 16: 217–241, 1990.PubMedGoogle Scholar
  198. 198.
    Zachariae H, Halkier-Sorenson L, Heickendorff L, Zachariae E, Hansen HE: Cyclosporin: a treatment of systemic sclerosis. Br J Dermatol 122: 677–681, 1990.PubMedCrossRefGoogle Scholar
  199. 199.
    Kahan A, Amor B, Menkes CJ, Shauch G: Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 87: 273–277, 1989.PubMedCrossRefGoogle Scholar
  200. 200.
    Freundlich B, Jimenez SA, STeen VD, Medsger TA, Szkolnicki M, Jaffe HS: Treatment of systemic sclerosis with recombinant gamma interferon: a phase I/II clinical trial. Arthritis Rheum 35: 1134–1142, 1992.PubMedCrossRefGoogle Scholar
  201. 201.
    Dau PC, Kahleh MB, Sagebiel RW: Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 24: 1128–1136, 1981.PubMedCrossRefGoogle Scholar
  202. 202.
    Hoxie HJ, Coggin CB: Renal infarction: statistical study of 205 cases and detailed report of an unusual case. Arch Intern Med 65: 587–594, 1940.CrossRefGoogle Scholar
  203. 203.
    Peterson NE, McDonald DF: Renal embolization. J Urol 100: 140–145, 1968.PubMedGoogle Scholar
  204. 204.
    Foley WJ, Kraft RO: Renal artery embolectomy. Arch Surg 103: 748–751, 1971.PubMedCrossRefGoogle Scholar
  205. 205.
    Gill TJ, Dammin GJ: Paradoxical embolism with renal failure caused by occlusion of the renal arteries. Am J Med 25: 780–787, 1958.PubMedCrossRefGoogle Scholar
  206. 206.
    Shabanah FH, Conolly JE, Martin DC: Acute renal artery occlusion. Surg Gynecol Obstet 131: 489–494, 1970.PubMedGoogle Scholar
  207. 207.
    Besareb A. Brown RS, Rubin NT, Salzman E, Withlin L, Steinman T, Atlia RR, Skillman JJ: Reversible renal failure following bacterial renal artery occlusive disease. Clinical features, pathology, and the role of surgical revascularization. JAMA 235: 2838–2841, 1975.Google Scholar
  208. 208.
    Arakawa K, Torii S, Kibuchi Y, Nakamura M: Delayed renin release in renal infarction. Arch Intern Med 129: 958–962, 1972.PubMedCrossRefGoogle Scholar
  209. 209.
    Arakawa K, Torii S, Naito S, Minohara A, Vemura N, Nakamura M: Plasma renin activity as a more specific diagnostic aid for renal ’mimciion.Arch Intern Med 125: 830–834, 1970.CrossRefGoogle Scholar
  210. 210.
    London IL, Hoffsten P, Perkoff GT, Pennington TG: Renal infarction. Elevation of serum and urinary lactic dehydrogenase (LDH). Arch Intern Med 121: 87–90, 1968.PubMedCrossRefGoogle Scholar
  211. 211.
    Duncan DA, Dexter RN: Anuria secondary to bilateral renal-artery embolism. N Engl J Med 266: 971–973, 1962.PubMedCrossRefGoogle Scholar
  212. 212.
    Smith SP, Hamburger RJ, Donohue JP, Grim CE: Occlusion of the artery to a solitary kidney. Restoration of renal function after prolonged anuria. JAMA 230:1306–1307Google Scholar
  213. 213.
    Kerr WK, Kyle VN, Kerestici AG, Smythe CA: Renal hypothermia. J Urol 84: 236–242, 1960.PubMedGoogle Scholar
  214. 214.
    Brest AN, Bower R, Heider C: Renal functional recovery following anuria secondary to renal artery embolism. JAMA 187: 540–542, 1964.PubMedCrossRefGoogle Scholar
  215. 215.
    Perkins RP, Jacobsen DS, Feder FP, Lipchik EO, Fine PH: Return of renal function after late embolectomy. N Engl J Med 276: 1194–1195, 1967.PubMedCrossRefGoogle Scholar
  216. 216.
    Millan VG, Sher MH, Deterling RA, Packard A, Morton JR, Harrington JT: Transcatheter thromboembolectomy. Arch Surg 113: 1086–1092, 1978.PubMedCrossRefGoogle Scholar
  217. 217.
    Fischer CP, Konnach JW, Cho KJ, Eckhauser FE, Stanley JC: Renal artery embolism: therapy with intra-arterial streptokinase infusion. J Urol 125:402104, 1981.Google Scholar
  218. 218.
    Lessman RK. Johnson SF, Coburn JW, Kaufman JJ: Renal artery embolism. Clinical features and long-term follow-up of 17 cases. Ann Intern Med 89: 477–482, 1978.PubMedCrossRefGoogle Scholar
  219. 219.
    Parker JM, Lord JO: Renal artery embolism. A case report with return of complete function of the involved kidney following anticoagulant therapy. J Urol 106: 339–341, 1971.PubMedGoogle Scholar
  220. 220.
    Moyer JD, Rao CN, Widrich WC, Olsson CA: Conservative management of renal artery embolus. J Urol 109: 138–143, 1973.PubMedGoogle Scholar
  221. 221.
    Flory CM: Arterial occlusions produced by emboli from eroded aortic atheromatous plaques. Am J Pathol 21: 549–565, 1945.PubMedGoogle Scholar
  222. 222.
    Retan JW, Miller RE: Microembolic complications of atherosclerosis. Literature review and report of a patient. Arch Intern Med 118: 534–545, 1966.PubMedCrossRefGoogle Scholar
  223. 223.
    Tunick PA, Perez JL, Kronzon I: Protruding atheromas in the thoracic aorta and systemic embolization. Ann Intern Med 115: 423–427, 1991.PubMedCrossRefGoogle Scholar
  224. 224.
    Kassirer JP: Atheroembolic renal disease. N Engl J Med 280: 812–818, 1969.PubMedCrossRefGoogle Scholar
  225. 225.
    Smith MC, Ghose M, Henry AR: Clinical spectrum of renal cholesterol embolization. Am J Med 71: 174–180, 1981.PubMedCrossRefGoogle Scholar
  226. 226.
    Fine MJ, Kapoor W, Falanga V: Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 38: 769–784, 1987.PubMedCrossRefGoogle Scholar
  227. 227.
    Jones DB, Iannaccone PM: Atheromatous emboli in renal biopsies. An ultrastructural study. Am J Pathol 78:261–270Google Scholar
  228. 228.
    Colt HG, Begg RJ, Saporito JJ, Cooper WM, Shapiro AP: Cholesterol emboli after cardiac catheterization: eight cases and review of the literature. Medicine 67:389100, 1988.Google Scholar
  229. 229.
    Thurbleck WM, Castleman B: Atheromatous emboli to the kidneys after aortic surgery. N Engl J Med 257:442-177,1957.Google Scholar
  230. 230.
    Harrington JT, Sommers SC, Kassirer JP: Atheromatous emboli with progressive renal failure. Renal arteriography as the probably inciting factor. Ann Intern Med 68: 152–160, 1968.PubMedCrossRefGoogle Scholar
  231. 231.
    Hyman BT, Landas SK, Ashman RF, Schleper RL, Robinson RA: Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 82: 1233–1237, 1987.PubMedCrossRefGoogle Scholar
  232. 232.
    Bruns FJ, Segel DP, Adler S: Control of cholesterol embolization by discontinuation of anticoagulant therapy. Am J Med Sci 275: 105–108, 1978.PubMedCrossRefGoogle Scholar
  233. 233.
    Handler FP: Clinical and pathological significance of atheromatous embolization with episodes of the etiology of renal hypertension. Am J Med 20: 366–373, 1956.PubMedCrossRefGoogle Scholar
  234. 234.
    Richardson JH, Alderfer HH, Reid JD: Response of eye and brain to microemboli. Ann Intern Med 57: 1013–1017, 1962.PubMedCrossRefGoogle Scholar
  235. 235.
    Case Records of Massachusetts General Hospital (Case 25–1967). N Engl J Med 276: 1368–1377, 1967.CrossRefGoogle Scholar
  236. 236.
    Richards AM, Eliot RS, Kanjub VI, Bloemendaal RD, Edwards JE: Cholesterol embolism. A multisystem disease masquerading as polyarteritis nodosa. Am J Cardiol 15: 696–707, 1965PubMedCrossRefGoogle Scholar
  237. 237.
    Levine J, Rennke HG, Idelson BA: Profound persistent eosinophilia in a patient with spontaneous renal atheroembolic disease. Am J Nephrol 12: 377–379, 1992.PubMedCrossRefGoogle Scholar
  238. 238.
    Schwartz MW, McDonald GB: Cholesterol embolization syndrome: occurrence after intravenous streptokinase therapy for myocardial infarction. JAMA 258: 1934–1937, 1987PubMedCrossRefGoogle Scholar
  239. 239.
    Kasinath BS: Eosinophilia as a clue to the diagnosis of atheroembolic renal disease. Arch Intern Med 147: 1384–1385, 1987.PubMedCrossRefGoogle Scholar
  240. 240.
    Cosio F, Zager R, Sharma H: Atheroembolic renal disease causes hypocomplementemia. Lancet 2: 118–121, 1985.PubMedCrossRefGoogle Scholar
  241. 241.
    Antonucci F, Pizzoliitlo S, Travaglini M: Atheroembolic renal disease: clinicopathologic correlations. Adv Exp Med Biol 252: 59–63, 1989.PubMedCrossRefGoogle Scholar
  242. 242.
    McGowan JA, Greenberg A: Cholesterol atheroembolic renal disease: report of 3 cases with emphasis on diagnosis by skin biopsy and extended survival. Am J Nephrol 6:135–139Google Scholar
  243. 243.
    Anderson WR, Richards AM: Evaluation of lower extremity muscle biopsies in the diagnosis of atherembolism. Arch Pathol 86: 535–541, 1968.PubMedGoogle Scholar
  244. 244.
    Mannesse CK, Blankestijn PJ, Manin’t VAJ, Schalekamp MAD: Renal failure and cholesterol crystal embolization: a report of 4 surviving cases and a review of the literature. Clin Nephrol 36: 240–245, 1991.PubMedGoogle Scholar
  245. 245.
    Siemons L, van der Henvel P, Parizel G, Bayssens N, DeBroe MF., Cuykens JJ: Peritoneal dialysis in acute renal failure due to cholesterol embolization: two cases of recovery of renal function and extended survival. Clin Nephrol 28:205–208Google Scholar
  246. 246.
    Baum NH, Moriel E, Carlton CE: Renal vein thrombosis. J Urol 119: 443–148, 1978.PubMedGoogle Scholar
  247. 247.
    Harrison CV, Milne MD, Steiner RE: Clinical aspects of renal vein thrombosis. Q J Med 25: 285–298, 1956.PubMedGoogle Scholar
  248. 248.
    McCarthy LJ, Titus JL, Daugherty GW: Bilateral renal vein thrombosis and the nephrotic syndrome in adults. Ann Intern Med 58: 837–857, 1963.PubMedCrossRefGoogle Scholar
  249. 249.
    Baird WL, Buchanan DP: The nephrotic syndrome following thrombosis of the inferior vena cava. Am J Med 32: 128–130, 1962.PubMedCrossRefGoogle Scholar
  250. 250.
    Llach F, Arieff AI, Massry SG: Renal vein thrombosis and nephrotic syndrome. A prospective study of 36 adult patients. Ann Intern Med 83: 8–14, 1975.PubMedCrossRefGoogle Scholar
  251. 251.
    Llach F, Papper S, Massry S: The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 69: 819–827. 1980.PubMedCrossRefGoogle Scholar
  252. 252.
    Harrington JT, Kassirer JP: Renal vein thrombosis. Annu Rev Med 33: 255–262, 1982.PubMedCrossRefGoogle Scholar
  253. 253.
    Llach F: Hypercoaguability, renal vein thromosis, and other thrombotic complications of the nephrotic syndrome. Kidney Int 28: 429–439, 1985.PubMedCrossRefGoogle Scholar
  254. 254.
    Trew PA, Biava CG, Jacobs RP, Hopper J: Renal vein thrombosis in membranous glomerulonephropathy. Incidence and association. Medicine 47: 269–335, 1968.Google Scholar
  255. 255.
    Rosenmann E, Pollak VE, Pirani CL: Renal vein thrombosis in the adult—a clinical and pathologic study based on renal biopsies. Medicine 47: 269–335, 1968.PubMedCrossRefGoogle Scholar
  256. 256.
    Huch KM, Wall BM, Cooke CR: Acute renal vein thrombosis in patients with spinal cord injury and secondary amyloidosis. Am J Med Sci 308: 119–122, 1994.PubMedCrossRefGoogle Scholar
  257. 257.
    McFarland JB: Renal venous thrombosis in children. Q J Med 34: 269–290, 1965.PubMedGoogle Scholar
  258. 258.
    Arneil GC, MacDonald AM, Murphy AV, Sweet EM: Renal vein thrombosis. Clin Nephrol 1: 119–131, 1973.PubMedGoogle Scholar
  259. 259.
    Wegner GP, Crummy AB, Flaherty TT, Hipona FA: Renal vein thrombosis: a roentgenographic diagnosis. JAMA 209: 1661–1667, 1969.PubMedCrossRefGoogle Scholar
  260. 260.
    Bernard DB: Extrarenal complications of the nephrotic syndrome. Kidney Int 33: 1184–1202, 1988.PubMedCrossRefGoogle Scholar
  261. 261.
    Kirulata HG, Bruce AW, Jarzylo SV, Morrin PAF: The protean manifestations of renal vein thrombosis in the adult. J Urol 115: 634–638, 1976.Google Scholar
  262. 262.
    Kanfer A, Kleinknecht D, Broyer M, Josso F: Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh 24: 562–571, 1970.PubMedGoogle Scholar
  263. 263.
    Kendall AG, Lohmann RC, Dossetor JB: Nephrotic syndrome: a hypercoagulable state. Arch Intern Med 127:1021— 1027, 1971.Google Scholar
  264. 264.
    Thomson C, Forbes DC, Prentice CRM, Kennedy AC: Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med 43: 399–407, 1974.PubMedGoogle Scholar
  265. 265.
    Nachman RL, Silverstein R: Hypercoagulable states. Ann Intern Med 119: 819–827, 1993.PubMedCrossRefGoogle Scholar
  266. 266.
    Love PE, Santoro SA: Antiphospholipid antibodies. Anticardiolipin and lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Arch Intern Med 112: 682–698, 1990.CrossRefGoogle Scholar
  267. 267.
    Hipona FA, Crummy AB: The roentgen diagnosis of renal vein thrombosis: clinical aspects. Am J Roentgen Radiat Ther Nucl Med 93: 122–131, 1966.CrossRefGoogle Scholar
  268. 268.
    Mulhern CB, Arger PH, Miller WT, Chait A: The specificity of renal vein thrombosis. Am J Roentgen Radiat Ther Nucl Med 125: 291–299, 1975.CrossRefGoogle Scholar
  269. 269.
    Rosenfield AT, Zeman RK, Cronan JJ, Taylor KJW: Ultrasound in experimental and clinical renal vein thrombosis. Radiology 137: 735–741, 1980.PubMedGoogle Scholar
  270. 270.
    Zerhouni EA, Barth KH, Ziegelman SS: Demonstration of venous thrombosis by computer tomography. Am J Roentgen Radiat Ther Nucl Med 134: 753–758, 1980.CrossRefGoogle Scholar
  271. 271.
    Gatewood OMB, Fishman EK, Burrow CR, Walker WG, Goldman SM, Ziegelman SS: Renal vein thrombosis in patients with nephrotic syndrome: CT diagnosis. Radiology 159: 117–122, 1986.PubMedGoogle Scholar
  272. 272.
    Tempany CM, Zerhouni EA: Clinical magnetic resonance imaging of the vascular system. Top Magn Reson Imaging 2: 13–30, 1990.PubMedCrossRefGoogle Scholar
  273. 273.
    Erantantoni JD, Ness P, Simon TL: Thrombolytic therapy. Current status. N Engl J Med 293: 1073–1076, 1975.CrossRefGoogle Scholar
  274. 274.
    Bromberg WD, Firlit CF: Fibrinolytic therapy for renal vein thrombosis in the child. J Urol 143: 86–88, 1990.PubMedGoogle Scholar
  275. 275.
    Kennedy JS, Gerety BM, Silverman R, Pattison ME, Siskind MS, Pond GD: Simultaneous renal arterial and venous thrombosis associated with idiopathic nephrotic syndrome: treatment with intra-arterial urokinase. Am J Med 90: 124–127, 1991.PubMedCrossRefGoogle Scholar
  276. 276.
    Segasothy M, Parameswaran V: Thrombolytic therapy in a patient with chronic renal vein thrombosis. Nephron 59: 168–169, 1991.PubMedCrossRefGoogle Scholar
  277. 277.
    Laville M, Aguilera D, Maillet PJ, Labeeuw M, Madona O, Zach P: The prognosis of renal vein thrombosis: a re-evaluation of 27 cases. Nephrol Dial Transplant 3: 247–256, 1988.PubMedGoogle Scholar
  278. 278.
    Hobbs DC, Twomey TM: Kinetics of polythiazide. Clin Pharmacol Ther 23: 241–246, 1978.PubMedGoogle Scholar
  279. 279.
    Beerman B, Groschinsky-Grind M: Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 12: 297–303, 1977.CrossRefGoogle Scholar
  280. 280.
    Dargie HJ, Allison ME, Kennedy AC, Gray AJ: High dose metolazone in chronic renal failure. Br Med J 1: 196–198, 1972.CrossRefGoogle Scholar
  281. 281.
    Tilsone WJ, Dargie HJ, Dargie EN, Morgan HG, Kennedy AC: Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther 16: 322–329, 1974.Google Scholar
  282. 282.
    Acchiardo SR, Skoutakis VA: Clinical efficacy, safety and pharmacokinetics of indapamide in renal impairment. Am Heart J 106: 237–244, 1983.PubMedCrossRefGoogle Scholar
  283. 283.
    Beerman B, Dalen E, Linstron B: Elimination of furosemide in healthy subjects and in those with renal failure. Clin Pharmacol Ther 22: 70–78, 1977.Google Scholar
  284. 284.
    Rane A, Villeneuve JP, Stone WJ, Wilkenson JR, Branch RA: Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 24: 199–207, 1978.PubMedGoogle Scholar
  285. 285.
    Schwartz FD, Pillay V, Kark RM: Ethacrynic acid: its usefulness and untoward effect. Am Heart J 79: 427–428, 1970.PubMedCrossRefGoogle Scholar
  286. 286.
    Davies DL, Lant AF, Millard NR, Smith AJ, Ward JW. Wilson GM: Renal action, therapeutic use and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther 15: 141–155, 1974.PubMedGoogle Scholar
  287. 287.
    Barclay JE, Lea HA: Clinical and pharmacokinetic studies of bumetanide in chronic renal failure. Postgrad Med J 51 (Suppl): 3–16, 1975.Google Scholar
  288. 288.
    Kramer WG, Rudy DW, Gehr TWB, Matzke GR, Sica DA, Brater DC: Torsemide pharmacokinetics and pharmacodynamics in patients with chronic renal insufficiency. In: Puschett SB, Greenberg A, eds, DIURETICS IV. Excerpta Medica, Amsterdam, pp 107–111, 1993.Google Scholar
  289. 289.
    Karin A: Spironolactone: disposition, metabolism, pharmacodynamics and bioavailability. Drug Metab Rev 8: 151–188, 1978.CrossRefGoogle Scholar
  290. 290.
    Knaut H, Schnippenkotter I, Wais U, Geissler H, Grebian B, Mutschler E: Diuretic activity and renal elimination of triamterene and metabolites in renal insufficiency. Kidney Int 13: 528–529, 1978.Google Scholar
  291. 291.
    Schwartz A, Seller R, Onesti G, Kim, Swartz C, Brest AN: Pharmacodynamic effects of a new potassium-sparing diuretic, amiloride. J Clin Pharmacol 9: 217–223, 1969.Google Scholar
  292. 292.
    Stenbock O, Myhre E, Rugstad HE, Arnold E, Hanson T: Pharmacokinetics of methyldopa in healthy man. Eur J Clin Pharmacol 12: 117–123, 1977.CrossRefGoogle Scholar
  293. 293.
    Myhre E, Brodwall EK, Stenbock O, Hanson T: Plasma turnover of methyldopa in advanced renal failure. Acta Med Scand 191: 343–347, 1972.PubMedGoogle Scholar
  294. 294.
    Yeh BK, Dayton PG, Waters WC: Removal of alpha methyldopa (Aldomet) in man by dialysis. Proc Soc Exp Biol Med 135: 840–843, 1970.PubMedCrossRefGoogle Scholar
  295. 295.
    Dollery CT, David DS, Draffon GH, Dargie JH, Dean CR, Reid JL, Clare RA, Murray S: Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19: 11–17, 1976.PubMedGoogle Scholar
  296. 296.
    Hulter HN, Licht JH, Ienicki LP, Singh S: Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency./Lab Clin Med 93: 223–231, 1979.Google Scholar
  297. 297.
    Stitzel RE: The biological fate of reserpine. Pharmacol Rev 28: 179–208, 1976.PubMedGoogle Scholar
  298. 298.
    Zoster IT, Johnson GE, DeVeber GA, Paul H: Excretion and metabolism of reserpine in renal failure. Clin Pharmacol Ther 14: 325–330, 1973.Google Scholar
  299. 299.
    Bauer JH: Effects of guanabenz therapy on renal function and body fluid composition. Arch Intern Med 143: 1163–1167, 1983.PubMedCrossRefGoogle Scholar
  300. 300.
    Carchman SH, Crowe JT: Steady-state plasma levels and pharmacokinetics of guanfacine in hypertensive patients with normal renal function. Clin Pharmacol Ther 37: 186–192, 1985.Google Scholar
  301. 301.
    Wilkinson R: (3-blockers and renal function. Drugs 23:195–206, 1982.Google Scholar
  302. 302.
    Johnsson G, Regardh CG: Clinical pharmacokinetics of p-adrenoreceptor blocking drugs. Clin Pharmacokinet 1: 233–263, 1976.PubMedCrossRefGoogle Scholar
  303. 303.
    Vincent J, Meredith PH, Eliott HL, Reid JL: The pharmacokinetics of doxazosin. Br J Clin Pharmacol 21: 521–524, 1986.PubMedCrossRefGoogle Scholar
  304. 304.
    Reidenberg MM, Drayer D, De Marco AL, Bello CT: Hydralazine elimination in man. Clin Pharmacol Ther 14: 970–977, 1973.PubMedGoogle Scholar
  305. 305.
    Talseth T: Studies on hydralazine: elimination and steady-state concentration in patients with impaired renal function. Eur J Clin Pharmacol 10: 311–317, 1976.PubMedCrossRefGoogle Scholar
  306. 306.
    Gottlieb TB, Thomas RC, Chedsey CA: Pharmacokinetic studies of minoxidil. Clin Pharmacol Ther 13: 436–441, 1972.PubMedGoogle Scholar
  307. 307.
    Lowenthal DT, Mutterperl RE, Zinns G: Bioavailability, pharmacokinetics and pharmacodynamics of minoxidil in chronic renal failure (abstract). Clin Pharmacol Ther 21: 109, 1977.Google Scholar
  308. 308.
    Asher JP, Murray KM: Use of angiotensin-converting-enzyme inhibitors in the management of renal disease. Clin Pharm 10: 25–31, 1991.PubMedGoogle Scholar
  309. 309.
    Rommel AJ, Pieridew AM, Heald A: Captopril elimination in chronic renal failure. Clin Pharmacol Ther 27: 282, 1980.Google Scholar
  310. 310.
    Todd PA, Heel RC: Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986.PubMedCrossRefGoogle Scholar
  311. 311.
    Lancaster SG, Todd PA: Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 35: 646–669, 1988.PubMedCrossRefGoogle Scholar
  312. 312.
    Wadsworth AW, Brogden RN: Quinapril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 41: 378–399, 1991.CrossRefGoogle Scholar
  313. 313.
    Balfour JA, Goa KL: Benazepril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 42: 511–539, 1991.PubMedCrossRefGoogle Scholar
  314. 314.
    Todd PA, Benfield P: Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 39: 110–135, 1990.PubMedCrossRefGoogle Scholar
  315. 315.
    Hui KK: Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 49: 457–467, 1991.PubMedCrossRefGoogle Scholar
  316. 316.
    Saltiel E: Felodipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension. Drugs 36: 387–428, 1988.PubMedCrossRefGoogle Scholar
  317. 317.
    Pederson OL, Knisell LR, Sihm I, Jespersen LT, Thomsen K: Long-term effects of isradipine on blood pressure and renal function. Am J Med 86 (Suppl 4A): 15–18, 1989.CrossRefGoogle Scholar
  318. 318.
    Sorkin EM, Clissald SP: Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties. Drugs 33: 296–245, 1987.PubMedCrossRefGoogle Scholar
  319. 319.
    Saruta T, Ishu M, Abe K, Iamura I: Efficacy and safety of amlodipine in hypertensive patients with renal dysfunction. Clin Cardiol 17: 317–324, 1994.PubMedCrossRefGoogle Scholar
  320. 320.
    Laher MS, Kelly JG, Doyle GD: Pharmacokinetics of amlopidine in renal impairment. J Cardiovasc Pharmacol 12 (Suppl 7): S60 - S63, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Garabed Eknoyan
    • 1
  1. 1.Department of MedicineBaylor College of MedicineHoustonUSA

Personalised recommendations